title: Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
abstract: We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial TH1 anticancer immune responses while suppressing the unwanted accumulation of regulatory T cells.
authors.affiliation: Cancer Division; Garvan Institute of Medical Research; Sydney, NSW Australia ; St. Vincent's Clinical School; University of New South Wales; Sydney, NSW Australia.
authors.forename: Alexander
authors.initials: A
authors.lastname: Swarbrick
authors.forename: Simon R
authors.initials: SR
authors.lastname: Junankar
authors.forename: Marcel
authors.initials: M
authors.lastname: Batten
keywords: 3-methylcholanthrene; Tregs; interferon γ; interleukin-27; polyomavirus middle T antigen (PyMT)-induced mammary carcinoma